Table 2.
Characteristics of PIMs at admission and at discharge among the 158 patients who survived until discharge
| Category | Intervention n = 31 |
Usual care n = 127 |
||||
|---|---|---|---|---|---|---|
| At admission | At discharge | p-value | At admission | At discharge | p-value | |
| Any PIMs,a n (%) | 29 (93.5) | 16 (51.6) | < 0.001 | 95 (74.8) | 87 (68.5) | 0.33 |
| Benzodiazepines, n (%) | 11 (35.5) | 7 (22.6) | 43 (33.9) | 37 (29.1) | ||
| PPIs, n (%) | 10 (32.3) | 4 (12.9) | 33 (26.0) | 31 (24.4) | ||
| Hypnoticsb, n (%) | 5 (16.1) | 2 (6.5) | 17 (13.4) | 13 (10.2) | ||
| Antipsychotics, n (%) | 4 (12.9) | 2 (9.8) | 12 (9.4) | 9 (7.1) | ||
| Anticholinergics, n (%) | 2 (6.5) | 1 (3.2) | 13 (10.2) | 12 (9.4) | ||
| H2-receptor antagonistsc, n (%) | 1 (3.2) | 0 (0.0) | 9 (7.1) | 8 (6.3) | ||
| Anticonvulsants, n (%) | 2 (6.5) | 2 (6.5) | 6 (4.7) | 8 (6.3) | ||
| Opioids, n (%) | 2 (6.5) | 2 (6.5) | 5 (3.9) | 3 (2.4) | ||
| SSRIs, n (%) | 1 (3.2) | 1 (3.2) | 4 (3.1) | 4 (3.1) | ||
| Others, n (%) | 5 (16.1) | 1 (3.2) | 12 (9.4) | 11 (8.7) | ||
aPIMs were defined based on the 2015 American Geriatric Society Beers Criteria
bThis category included non-benzodiazepine benzodiazepine receptor agonist hypnotics
cThis category included only H2-receptor antagonist use for dementia